Doxycycline
From Pharmacopedia
More actions
Doxycycline
Vibramycin, Doryx, Oracea, Adoxa, Monodox, Acticlate
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Pharmacy
Starting dose
100 mg PO BID; rickettsial 200 mg/d; doxy-PEP 200 mg within 72 hours after condomless sex
Preparations
50 mg, 75 mg, 100 mg, 150 mg tablets and capsules; delayed-release; suspension; IV
US FDA Max
~200 mg/d for most indications; higher doses for severe infections
Pharmacology
Routes
Oral, IV
Onset
Hours
Duration
12 hours
Half-life
16-22 hours[1]
Bioavailability
~95% (oral; reduced by dairy, antacids, iron via divalent-cation chelation, though less than for tetracycline itself)[1]
Pregnancy
Avoid in pregnancy and in children <8 years where alternatives exist (dental staining, possible effect on developing bone); life-threatening rickettsial disease is the recognized exception where benefit outweighs.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Doxycycline binds reversibly to the 30S bacterial ribosomal subunit and blocks aminoacyl-tRNA from accessing the A site, inhibiting protein synthesis; the resulting effect is bacteriostatic against a broad range of gram-positives, atypicals, spirochetes, and intracellular organisms.0 Pleiotropic non-antibiotic effects (matrix metalloproteinase inhibition) underlie efficacy in rosacea and the periodontitis-adjuvant indication at sub-antimicrobial doses. Photosensitivity, pill-induced esophagitis (take with water, remain upright), and esophageal/oral candidiasis are characteristic adverse effects[1].
References
- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Vibramycin (doxycycline), Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050006s083lbl.pdf